| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802021701014 | 202170101 | ZAVEDOS PD.INJ.SOL 5MG/VIAL ΒΤx1VIAL | 22.07 | 23.15 | 31.91 |
| 05/2018 | 2802021702011 | 202170201 | ZAVEDOS PD.INJ.SOL 10MG/VIAL ΒΤx1VIAL | 69.56 | 72.97 | 92.81 |
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
22 hours
The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.